Faron Pharmaceuticals presenting at the Proactive One2One Virtual Forum - 16th September 2021

Faron is a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system in order to tackle cancer and inflammation. Since our founding in 2007, our goal has been to develop a diverse and unique pipeline rooted in high quality science and innovation. Faron is focused on mastering immune modulation by harnessing endothelial receptors to control and mediate immune responses. We are disrupting the current treatment landscape with a novel pipeline of immune modulation based proprietary drug candidates with numerous applications tackling major unmet needs including immuno-oncology, and organ protection and regenerative medicine. Faron works today with tomorrow’s breakthroughs. Our main focus is on our core scientific and clinical development expertise and advancing our broad pipeline of novel programs including Bexmarilimab in oncology, Traumakine in organ protection and Haematokine in regenerative medicine. Working closely with our network of trusted strategic collaborators we are able to give our pipeline the greatest chances of success with a focus on improving the lives of patients suffering from devastating diseases.

Story by ProactiveInvestors